US20010008637A1 - Two-part capsule to accept pharmaceutical preparations for powder inhalers - Google Patents

Two-part capsule to accept pharmaceutical preparations for powder inhalers Download PDF

Info

Publication number
US20010008637A1
US20010008637A1 US09/800,647 US80064701A US2001008637A1 US 20010008637 A1 US20010008637 A1 US 20010008637A1 US 80064701 A US80064701 A US 80064701A US 2001008637 A1 US2001008637 A1 US 2001008637A1
Authority
US
United States
Prior art keywords
capsule
cap
capsule according
capsules
elevations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/800,647
Other languages
English (en)
Inventor
Dieter Hochrainer
Josef Eckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7876530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20010008637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US09/800,647 priority Critical patent/US20010008637A1/en
Publication of US20010008637A1 publication Critical patent/US20010008637A1/en
Priority to US10/740,225 priority patent/US20040131668A1/en
Priority to US11/970,982 priority patent/US8298575B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/072—Sealing capsules, e.g. rendering them tamper-proof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the invention relates to new two-part capsules for holding pharmaceutical preparations for use in powder inhalers.
  • Capsules with pharmaceutical preparations are often used in the therapy and diagnosis of illnesses.
  • the capsules can be orally administered or are used in certain medical apparatus such as powder inhalers.
  • the capsules consist of two parts, a capsule body (body) and a capsule cap (cap), which are pushed together telescopically.
  • multi-part capsules are also known.
  • the capsules generally consist of gelatine, especially hard gelatine.
  • the capsules occasionally consist of water-soluble synthetic materials easily digested by humans, in order for example to release the active ingredients in certain compartments of the gastrointestinal tract in the case of oral administration. Examples of various capsule materials are listed hereinafter.
  • EP 0143524 discloses a two-part capsule of material which is easily digestible by humans, preferably gelatine.
  • EP 0460921 describes capsules of chitosan and starch, grain powder, oligosaccharides, methacrylic acid-methylacrylate, methacrylic acid-ethylacrylate, hydroxypropylmethylcelluloseacetate, -succinate or -phthaleate.
  • the capsule material is distinguished by the contents not being released until they reach the large intestine.
  • GB 938828 discloses capsules for radioactive substances used in therapy or diagnosis.
  • the capsules comprise water-soluble gelatine, methylcellulose, polyvinylalcohol or water-soluble non-toxic thermoplasts.
  • capsules which are specially adapted for use in powder inhalers without necessarily being subjected to the conditions for oral administration, are previously not known in the prior art.
  • the capsules for powder inhalers comprise the same materials as are used for oral administration, usually hard gelatine. However, these materials are not specially perfected for use in powder inhalers.
  • One of the objectives of the present invention is to provide capsules which can be better adapted to the special conditions in powder inhalers.
  • the capsules which have hitherto been used in powder inhalers have various disadvantages as a result of their composition.
  • materials used in construction of the capsules can alter their characteristics dependent on the ambient air humidity and/or do not always have sufficient inherent stability.
  • such a capsule cannot for example be used in climatic zone 4 as a result of the high air humidity, since the capsule material absorbs the humidity to such a degree that the inherent stability is seriously affected and/or the humidity penetrates into the interior of the capsule. This has a negative effect on the pharmaceutical quality of the capsule's contents.
  • the said materials also have diverse disadvantages in other various stages in the life of the capsule from manufacturing up to utilisation, which affect the suitability of the capsule as a carrier for pharmaceutical preparations, the manner of administration of the contents, the perishability of the contents and/or the usability of the capsule in certain countries.
  • a further disadvantage of conventional capsule materials is that e.g. they tend to bind powder materials to themselves, especially when coated with a mould release agent which is often necessary for production of the capsule. In the case of capsules for inhalation purposes, this leads to difficulty in accurately metering the fine fraction which is to enter the lungs.
  • a further objective of the present invention is to provide capsules for powder inhalers which do not have the aforementioned problems of conventional capsules.
  • the present invention relates to a capsule for holding pharmaceutical preparations for powder inhalers with increased drug safety and capsules for pharmaceutical preparations for powder inhalers with improved adaptation to use in powder inhalers.
  • the capsules consist of water-insoluble, hydrophobic synthetic materials, which do not themselves substantially influence the pharmaceutical quality of the contents, but which improve the usability of the filled capsules with regard to their function, their longevity and/or the climatic zone, and are advantageous at various stages from production through to utilisation.
  • the capsules consist of two parts, a capsule body (body) and a capsule cap (cap), which can be connected together so as to form a stable enclosed hollow space of defined volume which contains the pharmaceutical formulation.
  • the dimensions of the capsule are chosen so that the capsule can be used with common powder inhalers which are used with capsules, such as those described for example in patent documents DE 33 45 722 (Inhaler Ingelheim M), EP 0 591 136 (Inhaler Ingelheim) or in the published German application DE 43 18 455 (“HandiHaler®”).
  • the synthetic material of the capsule is not digestible by humans, so that the active ingredient is not released when the capsule is taken orally. This has the advantage that inadvertent swallowing of the capsule cannot lead to a detrimental effect on health. This applies especially to small children or older people.
  • synthetic materials are used which can be processed using injection moulding or blow casting and/or synthetic materials where no mould release agent is necessary for their processing into capsule caps or capsule bodies, which can cause adhesion of the contents to the capsule wall.
  • This has the advantage that the interior of the cap or the body need not be cleaned from mould separation agent, in order for example to meet the official requirements (e.g. according to DAB (Deutsches maschiner Buch)), which restricts the use of mould release agents for primary packaging means.
  • the synthetic material does not exhibit any pronounced adhesion for pharmaceutical-chemical materials, especially for particles of lung-accessible size, so that when the capsule is used in one of the aforementioned inhalers, the entire contents of the capsule can be released.
  • This has the advantage that exact dosage, especially of the lung-accessible fine fraction, is possible.
  • the capsule consists of a synthetic material with a Shore hardness D of 65 to 73.
  • a synthetic material of this hardness does not shatter when it is pierced or cut open, but at the same time it is rigid enough so that the resulting hole does not close up again.
  • the advantage of such material is that no fragments can be forced out of the capsule during opening, piercing or slicing open of the capsule in the powder inhaler which can be breathed in during inhalation.
  • the synthetic material capsule is so stable that it can withstand a force along its longitudinal axis or transverse axis of up to 15 N.
  • the advantage of this is that the capsule is better adapted to the stress which acts upon it during manufacture, filling, packaging, transportation and the like.
  • the wall of the capsule has a steam permeability of less than 1.3 ⁇ 10 ⁇ 14 kg/(m 2 s Pa), preferably of 1.5 ⁇ 10 ⁇ 16 to 2 ⁇ 10 ⁇ 16 kg/(m 2 s Pa).
  • the synthetic material is polyethylene, especially polyethylene with a density of between 9000 and 10,000 kg/m 3 , preferably 9600 kg/m 3 (high-density polyethylene), polycarbonate, polyester, polypropylene or polyethyleneterephthalate.
  • the cap and the body have the shape of a cylinder with a round cross-section and a convex, practically hemispherical closed underside, and both consist of high-density polyethylene with a density of between 9500 and 10000 kg/m 3 .
  • the capsules according to the invention can be used in all kinds of powder inhalers where the preparation which is to be inhaled is administered by means of a capsule.
  • the cap and body of the capsule are of mutually-similar cylindrical shape, comprising an inherently closed jacket with, in each case, a closed end and an open end.
  • the shape and size of the cap and the capsule are such that the body can be pushed telescopically into the open end of the cap with its open end, so that the cap is attached solidly to the body.
  • the cap and body are provided with locking devices, which are advantageous for temporary and/or final closure of the capsule.
  • the elevations there are point-shaped elevations on the inner jacket of the cap and on the outer jacket of the body there are somewhat larger point-shaped recesses which are arranged so that the elevations engage with the recesses on closure of the capsule.
  • the elevations can be located on the outer jacket of the body and the recesses on the inner jacket of the cap. Arrangements are preferred where the elevations or recesses are respectively disposed in a ring or spiral shape about the jacket. Instead of the point-shaped design of the elevations and recesses, these can also run continuously around the cap or the body in a ring-shape.
  • one or more elevations running annularly around the inner jacket of the cap and the outer jacket of the body, are designed so that elevations on the cap are each positioned next to an elevation of the body when the capsule is closed.
  • annular recesses and/or elevations can be continuous or interrupted.
  • elevations are formed on the outside of the body near the open end and holes are formed in the cap near the open end so that the elevations of the body locate into the holes in the cap when the capsule is closed.
  • the elevations can be designed so that the cap can be opened at any time without damage to the capsule, or so that once closed, the capsule can no longer be opened without being damaged.
  • a bulge is designed on the outer side of the body, which runs around the body perpendicular to the connecting axis between the cap and the body.
  • the bulge serves as a stopper for the capsule when this is placed over the body, in order to prevent piercing of the cap with the body.
  • the area between the open end of the body and the bulge corresponds to the area of the body over which the cap can be pushed.
  • the bulge is located on the body so that the cap can be pushed far enough over the body to ensure good attachment between the cap and the body. That is, the bulge may not, for example, be located directly on the open side of the body.
  • the side of the bulge which faces the open end of the body stands as a vertical edge on the outer wall of the body so that the cap cannot be pushed over the bulge on closure.
  • the side of the bulge which faces towards the closed end of the body can be designed in the form of an almost right-angled edge or can taper towards the closed end of the body.
  • the formation of a practically right-angled edge can be advantageous where the capsule fits loosely into the capsule holder, whilst the version with the tapering bulge can be advantageous in the case of a tight fit.
  • the bulge can be continuous or interrupted.
  • the bulge tapers continuously to the closed end of the body and stands with its end oriented towards the open end of the body perpendicularly on the capsule body.
  • the height of the edge thus formed is such that, in the closed position of the capsule, the edge does not project beyond the cap, thus providing a flat transition from the cap to the body.
  • the thickness of the walls of the cap and the body can vary over the entire area.
  • the wall thickness is generally greater in the rounded areas of the cap or the body, or at that point in the body where the bulge is formed, than in the areas where the walls run straight.
  • the walls of the cap and the body have a thickness of 0.1 to 0.5 mm.
  • knobs are formed on the outside of the capsule, and in another embodiment there are three or more ribs, which run parallel to the longitudinal axis of the capsule.
  • the advantage of these devices is that the capsule can be removed from a capsule holder e.g. as used in the aforementioned powder inhalers, in such a way that it does not get damaged or break open.
  • the ribs or the knobs can run around the entire outside of the capsule or may only cover a part thereof. Alternatively, they may only be provided on the cap or only in the area of the body which is visible from outside in its closed state.
  • the ribs run parallel to the longitudinal axis of the capsule and ensure that the capsule is fixed vertically in the aforementioned capsule holder.
  • the ribs are preferably arranged so that the cross-section of the capsule does not have rotational symmetry about its central axis.
  • the ribs may be provided only in the area of the body which is visible when the capsule is closed. This embodiment prevents the capsule jamming in a capsule holder.
  • the ribs are designed so that the ends of the ribs which are orientated towards the open end of the body perform the function of the bulge, namely to act as a stopper for the cap, when the cap is attached to the body.
  • the jackets of the cap and the body describe a hollow cylinder with a round, oval, triangular, quadrilateral, hexagonal, octagonal or polygonal cross-section, where the respective upper side is open and the underside is closed.
  • the closed underside can be flat or convex.
  • the angled embodiments have the advantage that they can for example be stored in a more space-saving manner than the round embodiments.
  • the elongation of the capsule (distance from the closed end of the body to the closed end of the cap in relation to the diameter when the capsule is closed) is greater than 1, in one embodiment the elongation is 1 and in yet another embodiment the elongation is smaller than 1.
  • the latter has the advantage that the body has a larger opening for filling.
  • the cap and the body are designed so that the closed capsule is spherical, which can be advantageous for automatic loading of a powder inhaler with the capsule from a reservoir.
  • the joint between the cap and the body when the filled capsules are closed can be welded, adhesively bonded or wrapped, thus reducing the steam permeability to as little as a tenth.
  • the entire cap can be covered with a protective film.
  • the gap may be sealed with a filler.
  • Suitable fillers for filling the gap in this way are the pharmaceutically acceptable fillers such as Eudragit.
  • a filler of this kind can be inserted in the gap as a solution or suspension in a suitable, preferably highly volatile solvent.
  • Suitable solvents include fluorochlorohydrocarbons such as methylene chloride or chloroform, fluorohydrocarbons, alcohols such as methanol, ethanol, propanol, isopropanol, alkanes such as propane, hexane, heptane, ketones such as acetone, esters such as ethyl acetate, ethers such as dimethylether or diethylether or other liquids known from the prior art to be suitable for solutions or suspensions, especially volatile liquids and those which do not attack the capsule material, do not interact chemically with pharmaceutical compositions or alter their bioavailability.
  • fluorochlorohydrocarbons such as methylene chloride or chloroform
  • fluorohydrocarbons such as methylene chloride or chloroform
  • alcohols such as methanol, ethanol, propanol, isopropanol
  • alkanes such as propane, hexane, heptane
  • ketones such as
  • the solution or suspension with the filler must be of a nature and concentration such that the solution or suspension delivers sufficient filler into the gap so that, after the solvent has evaporated, the filler left behind provides a tight seal and at the same time the solution or suspension should not be of a nature and concentration such that it is too viscous to penetrate into the gap or be drawn into it by capillary action.
  • a solution of Eudragit and acetone is used to seal the gap.
  • the capsule is suitable for holding any kind of powdered pharmaceutical preparation which is suitable for inhalation.
  • the capsule contains cromoglycic acid, reproterol, beclomethasone, terbutaline, salbutamol, salmeterol, ketotifen, orciprenaline, fluticasone, insulin, ipratropium, dexamethasone, bambuterol, tiotropium, budesonide, fenoterol, clenbuterol, prednisolone, prednisone, prednylidene, methylprednisolone, formoterol, nedocromil, the salts or mixtures thereof or another cortisone preparation or atropine derivative suitable for inhalation purposes.
  • the capsule contains ipratropium bromide or tiotropium bromide.
  • FIG. 1 shows the simplest embodiment of the capsules according to the invention in lateral cross-section.
  • FIGS. 2 a and 2 b each show a different embodiment of the capsule with a tapering bulge on the body in lateral cross-section.
  • FIG. 3 shows an embodiment of the capsule with an angular bulge on the body in lateral cross-section.
  • FIG. 4 shows an embodiment of the capsule with a tapering bulge on the body and annular recess on the body and cap in lateral cross-section.
  • FIG. 5 shows an embodiment of the capsule with tapering bulge on the body and annular recess on the body and cap in frontal view.
  • FIG. 6 shows an embodiment of the capsule with tapering bulge on the body and point-shaped recesses or elevations on the body and cap in frontal view.
  • FIG. 7 shows an embodiment of the capsule with tapering bulge on the body and point-shaped elevations on the body and point-shaped holes in the cap in frontal view.
  • FIG. 8 shows an embodiment of the capsule with ribs on the body in frontal view.
  • FIG. 9 shows the capsule of FIG. 7 in horizontal cross-section.
  • FIGS. 10 a , 10 b and 10 c show embodiments of the capsule, each with a different cross-section.
  • FIG. 1 the simplest embodiment of the capsule according to the invention 1 is shown in cross-section.
  • the capsule 1 consists of the cap 2 and the body 3 , which are fitted telescopically one into the other.
  • the cap 2 and the body 3 are of the same shape and each has a convex underside 4 .
  • FIG. 2 a shows a cross-section of an embodiment where a bulge 5 is formed on the body 3 of the capsule 1 , this bulge tapering towards the closed end of the body.
  • the bulge 5 stands practically vertically on the body with its side orientated towards the open end of the body.
  • the edge thus formed demarcates the area of the body over which the cap 2 can be pushed telescopically.
  • FIG. 2 b Another embodiment is shown in FIG. 2 b .
  • the cross-section shows that this embodiment differs from that shown in FIG. 2 a in that the wall thickness of the cap 2 or the body 3 is not uniformly great over the entire area, but rather varies over individual partial areas.
  • the convex undersides 4 of the cap or the body each have a concave indentation at the vertex.
  • FIG. 3 an embodiment is represented where the bulge 5 sits on the body almost at right angles to the upper side of the body and also the underside of the body.
  • the embodiment of FIG. 4 represents a further development of the embodiment of FIG. 2 a , where an annular recess 6 or 7 is formed in cap 2 or body 3 in order to close the capsule 1 more satisfactorily.
  • FIG. 5 shows a front view of the embodiment shown in FIG. 4 as a cross-section.
  • FIG. 6 shows a further variant of the invention with point-shaped recesses 8 and 9 in front view.
  • FIG. 7 a variant of the capsule 1 is shown where elevations 10 are provided on the body 3 near the open end, and holes 11 are provided in the cap 2 near the open end so that the elevations 10 engage with the holes 11 when the capsule is closed.
  • FIG. 8 shows an embodiment of the capsule 1 from outside, where ribs 12 are provided on the body 3 .
  • FIG. 9 shows the body 3 of the embodiment in FIG. 7 in cross-section.
  • the cross-section shows that the three ribs 12 are not arranged with rotational symmetry about the central axis of the body.
  • FIGS. 10 a , 10 b and 10 c show a capsule 1 of quadrilateral, triangular and octagonal cross-section, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US09/800,647 1998-08-05 2001-03-07 Two-part capsule to accept pharmaceutical preparations for powder inhalers Abandoned US20010008637A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/800,647 US20010008637A1 (en) 1998-08-05 2001-03-07 Two-part capsule to accept pharmaceutical preparations for powder inhalers
US10/740,225 US20040131668A1 (en) 1998-08-05 2003-12-18 Two-part capsule to accept pharmaceutical preparations for powder inhalers
US11/970,982 US8298575B2 (en) 1998-08-05 2008-01-08 Two-part capsule to accept pharmaceutical preparations for powder inhalers

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19835346A DE19835346A1 (de) 1998-08-05 1998-08-05 Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
DE19835346.4 1998-08-05
US11321498P 1998-12-22 1998-12-22
US36591299A 1999-08-03 1999-08-03
US09/800,647 US20010008637A1 (en) 1998-08-05 2001-03-07 Two-part capsule to accept pharmaceutical preparations for powder inhalers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US36591299A Continuation 1998-08-05 1999-08-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/740,225 Continuation US20040131668A1 (en) 1998-08-05 2003-12-18 Two-part capsule to accept pharmaceutical preparations for powder inhalers

Publications (1)

Publication Number Publication Date
US20010008637A1 true US20010008637A1 (en) 2001-07-19

Family

ID=7876530

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/800,647 Abandoned US20010008637A1 (en) 1998-08-05 2001-03-07 Two-part capsule to accept pharmaceutical preparations for powder inhalers
US10/740,225 Abandoned US20040131668A1 (en) 1998-08-05 2003-12-18 Two-part capsule to accept pharmaceutical preparations for powder inhalers
US11/970,982 Expired - Fee Related US8298575B2 (en) 1998-08-05 2008-01-08 Two-part capsule to accept pharmaceutical preparations for powder inhalers

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/740,225 Abandoned US20040131668A1 (en) 1998-08-05 2003-12-18 Two-part capsule to accept pharmaceutical preparations for powder inhalers
US11/970,982 Expired - Fee Related US8298575B2 (en) 1998-08-05 2008-01-08 Two-part capsule to accept pharmaceutical preparations for powder inhalers

Country Status (35)

Country Link
US (3) US20010008637A1 (da)
EP (1) EP1100474B1 (da)
JP (1) JP2002522378A (da)
KR (1) KR100622291B1 (da)
CN (1) CN1151779C (da)
AR (1) AR023640A1 (da)
AT (1) ATE220542T1 (da)
AU (1) AU763266B2 (da)
BG (1) BG64115B1 (da)
BR (1) BR9912748A (da)
CA (1) CA2338323C (da)
CZ (1) CZ301558B6 (da)
DE (2) DE19835346A1 (da)
DK (1) DK1100474T5 (da)
EA (1) EA002186B1 (da)
EE (1) EE04451B1 (da)
ES (1) ES2180325T3 (da)
HK (1) HK1037975A1 (da)
HU (1) HU224955B1 (da)
ID (1) ID28290A (da)
IL (2) IL141124A0 (da)
MY (1) MY117930A (da)
NO (1) NO329078B1 (da)
NZ (1) NZ509977A (da)
PL (1) PL191231B1 (da)
PT (1) PT1100474E (da)
SI (1) SI1100474T1 (da)
SK (1) SK283568B6 (da)
TR (1) TR200100355T2 (da)
TW (1) TWI221420B (da)
UA (1) UA71920C2 (da)
UY (1) UY25637A1 (da)
WO (1) WO2000007572A2 (da)
YU (1) YU49388B (da)
ZA (1) ZA200100796B (da)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049311A1 (en) * 2001-01-30 2003-03-13 Mcallister Stephen Mark Pharmaceutical formulation
US20030125350A1 (en) * 1999-02-08 2003-07-03 Hassan Ian F. Combination of formoterol and a tiotropium salt
US20040115256A1 (en) * 2001-01-30 2004-06-17 Macallister Stephen Mark Pharmaceutical formulation
US20040136919A1 (en) * 2002-11-28 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040159322A1 (en) * 2003-01-14 2004-08-19 Boehringer Ingelheim International Gmbh Capsule for taking an active substance which can be inhaled
US20050084457A1 (en) * 2001-06-01 2005-04-21 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US20050249807A1 (en) * 2004-03-12 2005-11-10 Adrian Brown Pharmaceutical formulations
US20060157054A1 (en) * 2005-01-11 2006-07-20 Boehringer Lngelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
US7163693B1 (en) 1999-07-30 2007-01-16 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
US20070107722A1 (en) * 2005-11-15 2007-05-17 Hubert Hoelz Needle for piercing a powder capsule for inhalation
US20080160076A1 (en) * 1998-08-05 2008-07-03 Dieter Hochrainer Two-part capsule to accept pharmaceutical preparations for powder inhalers
US20090110723A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms
US20090108492A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Method and apparatus for manufacturing filled linkers
US20090110721A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Paneled capsule shells for release of pharmaceutical compositions
US20100022790A1 (en) * 2008-07-24 2010-01-28 Christian Dussarrat Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
US20100074947A1 (en) * 2008-06-13 2010-03-25 Adrian Brown Pharmaceutical Formulations
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US8673350B2 (en) 2003-07-21 2014-03-18 Capsugel Belgium Nv Pharmaceutical formulations
US20150136131A1 (en) * 2011-05-27 2015-05-21 Boehringer Ingelheim GmbH, Corporate Patents System composed of inhaler and capsule
US20180318171A1 (en) * 2017-05-03 2018-11-08 Garry Tsaur capsule sealing composition and its sealing method thereof
US20200197633A1 (en) * 2014-11-09 2020-06-25 Sipnose Ltd Bfs-ffs devices and methods for delivering a substance to a body cavity
US10888675B2 (en) * 2016-02-24 2021-01-12 Boehringer Ingelheim International Gmbh Inhaler
CN113933237A (zh) * 2021-10-20 2022-01-14 山西信谊通制药有限公司 一种阿莫西林胶囊检测装置及使用方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
DE10063957A1 (de) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Dopamin-Agonisten
WO2002036106A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
DE10137054A1 (de) * 2001-07-28 2003-02-13 Boehringer Ingelheim Pharma Verfahren zum Verschweißen von medizinischen Kapseln für die Inhalation, Inhalationskapseln und Apparat zum Verschweißen
US6949154B2 (en) 2001-07-28 2005-09-27 Boehringer Ingelheim Pharma Kg Method and apparatus for sealing medicinal capsules
GB0122031D0 (en) * 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
US7699052B2 (en) 2002-09-05 2010-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Apparatus for the dispensing of liquids, container cartridge suitable for this, and system comprising the apparatus for the dispensing of liquids, and the container cartridge
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
US7284553B2 (en) 2002-12-12 2007-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient
DE10258360A1 (de) * 2002-12-12 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator mit Kapselkammer zum Aufnehmen einer mit Wirkstoff gefüllten Einwegkapsel
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
CA2511555A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
DE10300984A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kapsel zur Aufnahme eines inhalativ applizierbaren Wirkstoffs
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
SI1615689T1 (sl) 2003-04-09 2016-05-31 Novartis Ag Naprava za aerosolizacijo s poravnalnim vodilom za prebadanje kapsule
ES2383367T5 (es) 2003-04-09 2021-03-31 Novartis Ag Aparato de pulverización en forma de aerosol con protección de entrada de aire
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE102004012973B4 (de) * 2004-03-17 2006-03-23 Josef Eckert Kapsel zur Aufnahme wenigstens einer pharmazeutischen Zubereitung, insbesondere für Pulverinhalatoren, sowie Kapselkette bestehend aus mehreren solcher Kapseln
CA2567785A1 (en) 2004-06-21 2006-01-05 Nektar Therapeutics Composition comprising amphotericin b methods and systems
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2006031712A2 (en) 2004-09-13 2006-03-23 Oriel Therapeutics, Inc. Tubular dry powder drug containment systems, associated inhalers and methods
GB0503738D0 (en) * 2005-02-23 2005-03-30 Optinose As Powder delivery devices
DE102005022862A1 (de) * 2005-05-18 2006-12-14 Airsec S.A.S Kapseln für Inhalatoren
US8377471B2 (en) * 2005-08-09 2013-02-19 Capsugel Belgium Nv Container
NL1033047C2 (nl) * 2006-12-13 2008-06-16 Pharmachemie Bv Capsule, gevuld met een medicijn, in het bijzonder een inhaleerbaar medicijn.
DE102007036411A1 (de) 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
DE102007033861A1 (de) 2007-07-20 2009-07-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
JP5667874B2 (ja) 2007-10-19 2015-02-12 ファイザー・プロダクツ・インク マルチコンパートメント容器
DE102007052871A1 (de) 2007-11-02 2009-05-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kapsel zur Aufnahme von pharmazeutischen Wirkstoffformulierungen
DE102007058112A1 (de) 2007-12-03 2009-06-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator mit Wirkstofftablette
BRPI0821111A2 (pt) * 2007-12-05 2015-06-16 Novartis Ag Recptáculo para uma formulação farmacêutica aerossoliza´vel
MX2010012452A (es) 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
AT507631B1 (de) 2008-11-26 2012-05-15 Haas Rouven Mag Vorrichtung zum ansaugen von pulver- oder granulat-material und kapsel hierfür
PL2413902T3 (pl) 2009-03-18 2020-01-31 Incarda Therapeutics, Inc. Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
US8746244B2 (en) 2009-10-02 2014-06-10 Boehringer Ingelheim International Gmbh Powder inhaler
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909790A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, formoterol ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
DE102010002604A1 (de) * 2010-03-05 2011-09-08 Robert Bosch Gmbh Kapsel zur Aufnahme eines Mediums und Verfahren zur Herstellung der Kapsel
EP2614848B1 (de) 2012-01-13 2020-07-01 Boehringer Ingelheim International GmbH Inhalator und Kapsel für einen Inhalator
WO2013174752A2 (de) 2012-05-21 2013-11-28 Boehringer Ingelheim International Gmbh System aus inhalator und kapsel
DE202011102694U1 (de) 2011-06-29 2011-12-19 Zisser Gmbh Inhalationsgerät für Heimanwender
JP6365848B2 (ja) * 2012-05-21 2018-08-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器及びカプセルで構成されたシステム
WO2016014153A1 (en) * 2014-07-23 2016-01-28 Microdose Therapeutx, Inc. Dry powder nebulizer
DE102015108931B3 (de) * 2015-06-05 2016-06-09 Gerresheimer Regensburg Gmbh Gitterelement für einen Inhalator
DE102015109996B3 (de) 2015-06-22 2016-07-28 Gerresheimer Regensburg Gmbh Einrichtung zum Öffnen von Kapseln
KR101748796B1 (ko) 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常
WO2017144386A1 (de) 2016-02-24 2017-08-31 Boehringer Ingelheim International Gmbh Inhalator
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US20200138794A1 (en) 2017-08-15 2020-05-07 Thomas Julius Borody Novel parasite therapy
EP3768378A4 (en) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596591A (en) * 1898-01-04 Track device for operating signals
GB691696A (en) 1950-10-05 1953-05-20 Becton Dickinson Co Improvements relating to hypodermic injection apparatus
US2718980A (en) * 1951-10-02 1955-09-27 Robinson William H Container seal
NL269886A (da) * 1960-10-04
US3285408A (en) * 1964-10-16 1966-11-15 Lilly Co Eli Capsule with integral locking band
US3623997A (en) * 1966-06-06 1971-11-30 Ncr Co Wall-sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material
US3949751A (en) * 1970-03-03 1976-04-13 Fisons Limited Method and device for dispensing medicament to the body
US3664495A (en) * 1970-12-21 1972-05-23 Parke Davis & Co Locking capsule
IT941426B (it) * 1971-07-17 1973-03-01 Isf Spa Inalatore a camera di turbinio per sostanze medicamentose polveriformi
US3823843A (en) * 1972-10-26 1974-07-16 Lilly Co Eli Locking capsule
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) * 1974-03-18 1977-05-30 Isf Spa Inalatore
US4040536A (en) * 1975-05-05 1977-08-09 R. P. Scherer Corporation Locking hard gelatin capsule
US4880547A (en) * 1975-06-30 1989-11-14 Kenji Etani Methods for water treatment
US4692314A (en) * 1975-06-30 1987-09-08 Kenji Etani Water treatment systems
JPS5352619A (en) 1976-10-25 1978-05-13 Shin Etsu Chem Co Ltd Enteric capsule
GB1598081A (en) * 1977-02-10 1981-09-16 Allen & Hanburys Ltd Inhaler device for dispensing medicaments
DE2722822C2 (de) * 1977-05-20 1984-11-08 Capsugel AG, Basel Verfahren zum Herstellen einer zum Aufnehmen eines viskosen Stoffes, insbesondere eines flüssigen Arzneimittels, geeigneten Steckkapsel
US4192304A (en) * 1978-03-14 1980-03-11 Johnson & Johnson Intravenous catheter assembly with fluid flow restriction capability
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
GB2064336B (en) * 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
ES506585A0 (es) * 1980-10-30 1982-09-01 Riker Laboratories Inc Un dispositivo para facilitar la inhalacion oral de medica- mentos en forma de polvo
GB2095497B (en) * 1981-03-24 1984-08-15 Racal Communications Equip Improvements in and relating to direction finding
ATE27546T1 (de) * 1982-10-29 1987-06-15 Warner Lambert Co Faelschungssichere kapseln.
US4656066A (en) * 1982-12-20 1987-04-07 Warner-Lambert Company Apparatus and method for sealing capsules
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
US4535567A (en) * 1983-08-26 1985-08-20 Seaborn Development, Inc. Computer magnetic media burnisher
GB8325529D0 (en) * 1983-09-23 1983-10-26 Lilly Industries Ltd Medicinal forms
US4738724A (en) * 1983-11-04 1988-04-19 Warner-Lambert Company Method for forming pharmaceutical capsules from starch compositions
DE3345722A1 (de) * 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
US4667498A (en) * 1984-06-29 1987-05-26 Sauter Manufacturing Corp. Method and apparatus of making gelatine capsule forming pins having a rounded locking groove
US4883182A (en) * 1985-05-31 1989-11-28 Hughes Raymond J Tamper evident capsule and insert device
US4648532A (en) * 1986-05-09 1987-03-10 Green Russell D Mixing and discharge capsule
US4793493A (en) * 1986-09-18 1988-12-27 Makiej Jr Walter J Multidose capsules
KR890003520Y1 (ko) * 1986-12-20 1989-05-27 주식회사 서흥캅셀 의약용 캅셀
GB8721455D0 (en) * 1987-09-11 1987-10-21 Lilly Industries Ltd Capsules
US4863017A (en) * 1988-11-09 1989-09-05 Vlock D G Amalgam capsule
US5342624A (en) * 1989-02-16 1994-08-30 British Technology Group Ltd. Dispensing device
IT1228460B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore monouso con capsula pre-forata
DE3927170A1 (de) * 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
EP0607321A1 (en) * 1991-10-10 1994-07-27 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5417337A (en) * 1991-11-12 1995-05-23 Robbins, Iii; Edward S. Reusable and re-collapsible container and associated cap
JPH0774149B2 (ja) 1991-12-27 1995-08-09 藤本製薬株式会社 硬ゼラチンカプセル
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5388698A (en) * 1992-02-03 1995-02-14 Wakao; Hiroshi Pocket carrier for dispensing products in precise quantitites
GB9223172D0 (en) * 1992-11-05 1992-12-16 Scherer Corp R P Capsule construction
GB9223144D0 (en) * 1992-11-05 1992-12-16 Scherer Corp R P Controlled release device
EP0597136A1 (de) 1992-11-08 1994-05-18 Prenco Ag Vorrichtung zum Abfördern und Reinigen von Lötrauch
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
US5396986A (en) * 1993-06-16 1995-03-14 Special Metals Corporation Mixing capsule having three tubular members
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
JPH07118143A (ja) 1993-10-18 1995-05-09 Bayer Yakuhin Kk ラグタイム制御型カプセル剤
FR2715299B1 (fr) * 1994-01-21 1996-06-14 Georges Serge Grimberg Médicament ayant une présentation pédiatrique facilitant son absorption par un enfant.
PT101450B (pt) * 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US5641510A (en) * 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
JP3455789B2 (ja) 1995-02-28 2003-10-14 株式会社大塚製薬工場 複室容器用フィルム及び複室容器
JP3028641U (ja) 1995-09-23 1996-09-13 スー ヘング カプセル カンパニー リミテッド 薬品又は食品のカプセル
KR0124764Y1 (ko) * 1995-09-23 1998-09-15 양주환 의약 및 식품용 하드 공 캅셀
JPH09104060A (ja) 1995-10-12 1997-04-22 Sumitomo Bakelite Co Ltd 医薬品包装用ポリプロピレン系シート及びその製造方法
JPH09193963A (ja) 1996-01-19 1997-07-29 Material Eng Tech Lab Inc 炭酸塩又は重炭酸塩を充填した樹脂容器の包装方法
JP3328132B2 (ja) * 1996-03-21 2002-09-24 株式会社ユニシアジェックス 吸入式投薬器
PT101988B (pt) * 1997-04-04 2004-02-27 Hovione Farmaciencia Sa Sistema de orientacao e posicionamento de um objecto
GB9805102D0 (en) * 1998-03-10 1998-05-06 Ciba Geigy Ag Device
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
DE19961311A1 (de) * 1999-12-18 2001-07-26 Bayerische Motoren Werke Ag Batteriesensorvorrichtung
US6949154B2 (en) * 2001-07-28 2005-09-27 Boehringer Ingelheim Pharma Kg Method and apparatus for sealing medicinal capsules
JP3750994B2 (ja) * 2001-11-16 2006-03-01 東京応化工業株式会社 ポジ型ホトレジスト組成物および傾斜インプランテーションプロセス用薄膜レジストパターンの形成方法
WO2003057593A1 (en) * 2001-12-21 2003-07-17 Nektar Therapeutics Capsule package with moisture barrier
US20030183548A1 (en) * 2002-04-02 2003-10-02 Oertel Fritz J. Packing capsule
US20040025876A1 (en) * 2002-05-07 2004-02-12 Danforth Miller Capsules for dry powder inhalers and methods of making and using same
US6941980B2 (en) * 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
US7284553B2 (en) * 2002-12-12 2007-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient
US6941954B1 (en) * 2003-02-20 2005-09-13 Michele Belcher Fingernail protection device
DE10352277A1 (de) * 2003-11-08 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298575B2 (en) 1998-08-05 2012-10-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule to accept pharmaceutical preparations for powder inhalers
US20080160076A1 (en) * 1998-08-05 2008-07-03 Dieter Hochrainer Two-part capsule to accept pharmaceutical preparations for powder inhalers
US20060083692A1 (en) * 1999-02-08 2006-04-20 Hassan Ian F Combination of formoterol and a tiotropium salt
US20030125350A1 (en) * 1999-02-08 2003-07-03 Hassan Ian F. Combination of formoterol and a tiotropium salt
US20100119597A1 (en) * 1999-07-30 2010-05-13 Clarke Allan J Multi-component pharmaceutical dosage form
US7163693B1 (en) 1999-07-30 2007-01-16 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
US8440224B2 (en) 1999-07-30 2013-05-14 Capsugel Belgium Nv Multi-component pharmaceutical dosage form
US7691407B2 (en) 1999-07-30 2010-04-06 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
US20070087049A1 (en) * 1999-07-30 2007-04-19 Smithkline Beecham Plc Multi-Component Pharmaceutical Dosage Form
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US8361498B2 (en) 2001-01-30 2013-01-29 Capsugel Belgium Nv Pharmaceutical formulation
US8367101B2 (en) 2001-01-30 2013-02-05 Capsugel Belgium Nv Pharmaceutical formulation
US20110123608A1 (en) * 2001-01-30 2011-05-26 Smithkline Beecham Limited Pharmaceutical formulation
US20040115256A1 (en) * 2001-01-30 2004-06-17 Macallister Stephen Mark Pharmaceutical formulation
US20030068369A1 (en) * 2001-01-30 2003-04-10 Mcallister Stephen Mark Pharmaceutical formulation
US7842308B2 (en) 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US20030049311A1 (en) * 2001-01-30 2003-03-13 Mcallister Stephen Mark Pharmaceutical formulation
US20050084457A1 (en) * 2001-06-01 2005-04-21 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20090137621A1 (en) * 2001-06-01 2009-05-28 Boehringer Ingelheim Pharma Kg Capsules Containing Inhalable Tiotropium
US20040136919A1 (en) * 2002-11-28 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040159322A1 (en) * 2003-01-14 2004-08-19 Boehringer Ingelheim International Gmbh Capsule for taking an active substance which can be inhaled
US7878193B2 (en) * 2003-01-14 2011-02-01 Boehringer Ingelheim International Gmbh Capsule for taking an active substance which can be inhaled
US20090181191A1 (en) * 2003-01-14 2009-07-16 Boehringer Ingelheim International Gmbh Capsule for taking an active substance which can be inhaled
US8001965B2 (en) 2003-01-14 2011-08-23 Boehringer Ingelheim International Gmbh Capsule for taking an active substance which can be inhaled
US8673350B2 (en) 2003-07-21 2014-03-18 Capsugel Belgium Nv Pharmaceutical formulations
US20070178156A1 (en) * 2004-03-12 2007-08-02 Adrian Brown Pharmaceutical formulations
US8147871B2 (en) 2004-03-12 2012-04-03 Capsugel Belgium Bvba Pharmaceutical formulations
US20050249807A1 (en) * 2004-03-12 2005-11-10 Adrian Brown Pharmaceutical formulations
US20060157054A1 (en) * 2005-01-11 2006-07-20 Boehringer Lngelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
US8662076B2 (en) * 2005-01-11 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
US9604017B2 (en) * 2005-11-15 2017-03-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Needle for piercing a powder capsule for inhalation
US20070107722A1 (en) * 2005-11-15 2007-05-17 Hubert Hoelz Needle for piercing a powder capsule for inhalation
US8454992B2 (en) 2007-10-15 2013-06-04 Capsugel Belgium Nv Paneled capsule shells for release of pharmaceutical compositions
US20090108492A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Method and apparatus for manufacturing filled linkers
US20090110723A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms
US20090110721A1 (en) * 2007-10-15 2009-04-30 Mcallister Stephen Mark Paneled capsule shells for release of pharmaceutical compositions
US8293159B2 (en) 2007-10-15 2012-10-23 Capsugel Belgium Method and apparatus for manufacturing filled linkers
US20100074947A1 (en) * 2008-06-13 2010-03-25 Adrian Brown Pharmaceutical Formulations
US8236979B2 (en) 2008-07-24 2012-08-07 American Air Liquide, Inc. Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
US20100022790A1 (en) * 2008-07-24 2010-01-28 Christian Dussarrat Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
US20150136131A1 (en) * 2011-05-27 2015-05-21 Boehringer Ingelheim GmbH, Corporate Patents System composed of inhaler and capsule
US10500355B2 (en) * 2011-05-27 2019-12-10 Boehringer Ingelheim International Gmbh System composed of inhaler and capsule
US20200197633A1 (en) * 2014-11-09 2020-06-25 Sipnose Ltd Bfs-ffs devices and methods for delivering a substance to a body cavity
US11992604B2 (en) * 2014-11-09 2024-05-28 Sipnose Ltd. Devices and methods for delivering a substance to a body cavity
US10888675B2 (en) * 2016-02-24 2021-01-12 Boehringer Ingelheim International Gmbh Inhaler
US20180318171A1 (en) * 2017-05-03 2018-11-08 Garry Tsaur capsule sealing composition and its sealing method thereof
US10729619B2 (en) * 2017-05-03 2020-08-04 Garry Tsaur Capsule sealing composition and its sealing method thereof
CN113933237A (zh) * 2021-10-20 2022-01-14 山西信谊通制药有限公司 一种阿莫西林胶囊检测装置及使用方法

Also Published As

Publication number Publication date
KR20010072222A (ko) 2001-07-31
ATE220542T1 (de) 2002-08-15
EE200100073A (et) 2002-06-17
ID28290A (id) 2001-05-10
AU5730499A (en) 2000-02-28
CN1311668A (zh) 2001-09-05
UA71920C2 (en) 2005-01-17
EA002186B1 (ru) 2002-02-28
DE59902055D1 (de) 2002-08-22
AU763266B2 (en) 2003-07-17
IL141124A (en) 2006-12-10
BG64115B1 (bg) 2004-01-30
MY117930A (en) 2004-08-30
NZ509977A (en) 2003-11-28
US8298575B2 (en) 2012-10-30
BR9912748A (pt) 2001-05-15
WO2000007572A2 (de) 2000-02-17
EE04451B1 (et) 2005-04-15
HK1037975A1 (en) 2002-03-01
EP1100474A2 (de) 2001-05-23
SK1692001A3 (en) 2001-09-11
CZ301558B6 (cs) 2010-04-14
ES2180325T3 (es) 2003-02-01
IL141124A0 (en) 2002-02-10
HUP0103490A3 (en) 2002-11-28
DK1100474T3 (da) 2002-10-14
US20080160076A1 (en) 2008-07-03
JP2002522378A (ja) 2002-07-23
NO20010535L (no) 2001-01-31
YU5401A (sh) 2003-10-31
CA2338323A1 (en) 2000-02-17
EA200100176A1 (ru) 2001-08-27
SK283568B6 (sk) 2003-09-11
DK1100474T5 (da) 2002-12-02
KR100622291B1 (ko) 2006-09-11
CA2338323C (en) 2009-06-09
HUP0103490A2 (hu) 2002-05-29
ZA200100796B (en) 2002-05-29
DE19835346A1 (de) 2000-02-10
EP1100474B1 (de) 2002-07-17
TR200100355T2 (tr) 2001-06-21
TWI221420B (en) 2004-10-01
PL191231B1 (pl) 2006-03-31
BG105189A (en) 2001-07-31
NO329078B1 (no) 2010-08-16
CZ2001444A3 (cs) 2001-07-11
YU49388B (sh) 2005-11-28
CN1151779C (zh) 2004-06-02
NO20010535D0 (no) 2001-01-31
PT1100474E (pt) 2002-12-31
UY25637A1 (es) 2000-02-23
AR023640A1 (es) 2002-09-04
WO2000007572A3 (de) 2000-05-11
PL346168A1 (en) 2002-01-28
SI1100474T1 (en) 2002-12-31
US20040131668A1 (en) 2004-07-08
HU224955B1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
CA2338323C (en) Two-piece capsule for receiving pharmaceutical preparations for powder inhalers
EP1883400B1 (de) Kapseln für inhalatoren
US8662076B2 (en) Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
JP4866242B2 (ja) 吸入器
MXPA01001312A (en) Two-piece capsule for receiving pharmaceutical preparations for powder inhalers

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION